Previous 10 | Next 10 |
Summary The science is as exciting as it gets - precision gene editing! Verve Therapeutics is working to provide new alternatives for the treatment of cardiovascular disease (CVD). While the science is exciting and the market opportunity very significant, the valuation may not...
The following slide deck was published by Verve Therapeutics, Inc. in conjunction with this event. For further details see: Verve Therapeutics (VERV) Investor Presentation - Slideshow
Verve Therapeutics (NASDAQ: VERV) , a clinical-stage gene-editing biopharmaceutical that focuses on cardiovascular therapies, saw its share price plummet 26.33% as of Monday afternoon. The stock closed on Friday at $31.29 and opened on Monday at $24.45. It fell to as low as $21.62 b...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock IAA (NYSE: IAA ) stock is climbing higher on Monday thanks to a massive acquisition deal with Ritchie Bros Auctioneers (NYSE: RBA ). Ritchie Bros have agreed to acquire IAA in a dea...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: JHVEPhoto / Shutterstock.com Verve Therapeutics (NASDAQ: VERV ) stock is taking a beating on Monday following bad news from the FDA. The unfortunate news for VERV shareholders is the FDA putting the ...
Verve Therapeutics press release ( NASDAQ: VERV ): Q3 GAAP EPS of -$0.79 misses by $0.06 . Revenue of $0.93M beats by $0.1M . Cash, cash equivalents and marketable securities were $550.7 million as of September 30, 2022, as compared to $360.4 million as of Dece...
Verve Therapeutics, Inc. ( NASDAQ: VERV ) lost ~22% pre-market Monday after the genetic medicines company announced that the FDA has placed on hold its Investigational New Drug application (IND) for its gene editing candidate VERVE-101. Submitting the IND in October, Ver...
VERVE-101 Investigational New Drug Application Placed on Hold by U.S. Food and Drug Administration Dosing Completed in First Dose Cohort of the heart-1 Clinical Trial of VERVE-101 in Patients with HeFH; Independent Data Safety Monitoring Board Recommended Proceeding to Second Do...
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that preclinical data supporting VERVE-101 as a treatmen...
Summary Prime Medicine's technology originated at Harvard/MIT and has been termed as CRISPR 3.0. Beam Therapeutics partnership in sickle cell disease and the experienced management add confidence in the Prime Editing technology. The key pipeline programs could have a peak reve...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities are encouraged to obtain additional informat...
2024-04-06 09:50:00 ET Verve Therapeutics (NASDAQ: VERV) saw its shares crater by 36% on April 2 when it reported that a serious mishap had occurred in one of its clinical trials. Understandably, investors may now question whether the gene-editing biotech has a shot at recovering, o...